eMC Medicine Guides  
The electronic Medicines Compendium (eMC) contains information about UK licensed medicines.
go to eMC homepage
Search for:  
  Advanced Search

Celgene Ltd
1 Longwalk Road, Stockley Park, Uxbridge, UB11 1DB , UK
Telephone: +44 (0)208 831 8300
Medical Information Direct Line: UK: 08448 010 045 Ireland: 1800 333 111
Medical Information e-mail: medinfo.uk.ire@celgene.com
Medical Information Fax: UK: 08448 010 046 Ireland: 1800 333 112

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?
Summary of Product Characteristics last updated on the eMC: 16/08/2011
SPC Refludan 50 mg powder for solution for injection or infusion

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 16/08/2011 and displayed until Current
Reasons for adding or updating:
  • Change to section 4.8 - Undesirable Effects
  • Change to section 7 - Marketing Authorisation Holder
  • Change to section 10 date of revision of the text
  • Correction of spelling/typing errors
  • Change to MA holder contact details
Date of revision of text on the SPC:   11-Aug-2011
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company
Section 4.8 - correction of typing error from Refuldan to Refludan.

Section 7 - MA Holders address updated

Section 10 - Date of revision updated to 11 August 2011
Updated on 04/09/2007 and displayed until 16/08/2011
Reasons for adding or updating:
  • Change to section 9 - Date of first Authorisation/renewal of the Authorisation
Date of revision of text on the SPC:   03/2007
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company
Section 4.8 (undesirable effects) - Brought in line with MedDRA
 
Section 9 - Change to Date of Renewal
Updated on 15/02/2007 and displayed until 04/09/2007
Reasons for adding or updating:
  • New SPC for eMC ie an SPC for an existing product, but one that is new for the eMC

Active Ingredients/Generics

 
  lepirudin